

See You At



INTERNATIONAL
CONFERENCE ON

FATTY LIVER

Seville, Spain
1-3 June 2017

www.icfl.kenes.com



THURSDAY, JUNE 1, 2017

Registration opens at 10:00

Program as of August 2016, subject to change

Time	Hall A	Hall B
13:00-14:00	Industry Session: Workshop / Symposium	Industry Session: Workshop / Symposium
14:00-15:00	Industry Session: Workshop / Symposium	Industry Session: Workshops / Symposium
15:00-16:00	Industry Session: Workshop / Symposium	Industry Session: Workshops / Symposium
16:00-16:30	Session 1: Introduction Introduction of the Program and its Objectives Keynote Lecture: The social, economic and public health impact of obesity	
16:30-17:30	Session 2: Defining NAFLD • Histological Definition of NAFLD • Clinical Laboratory Definition of NAFLD Panel Discussion	
17:30-18:00	Coffee Break	
18:00-19:30	Session 3: Recognizing NAFLD in your practice • How common is NASH in your diabetes clinic? • How common is NASH in primary care? • Why should you care about NAFLD? Panel Discussion	
19:30-21:00	Opening Ceremony followed by Networking Reception	



INTERNATIONAL CONFERENCE ON
FATTY LIVER



FRIDAY, JUNE 2, 2017

Time	Hall A	Hall B
08:00-10:00	Session 4: NASH and Cardiovascular Disease • NAFLD and cardiovascular disease- weighing the evidence critically • Atherogenic dyslipidemia and NAFLD • Cardiomyopathy associated with NAFLD • Coagulation and NAFLD Panel Discussion	
10:00-10:30	Coffee Break , Exhibition & Poster Viewing	
10:30-12:30	Session 5: Diabetes and NAFLD • Diabetes and NAFLD- is it one disease two target organs • Towards Diabetes Cure-implications for NAFLD • Gastrointestinal Lipid signaling and the Metabolic Syndrome THE GREAT DEBATE: Will NAFLD become an irrelevant clinical entity with tight glycemic control Panel Discussion	
12:30-14:00	Lunch, Exhibition & Poster Viewing	
12:30-14:00	Industry Session: Workshops / Symposium	Industry Session: Workshops / Symposium
14:00-15:30	Session 6: Drug safety in a primary care setting • What every doctor should know about liver-related drug safety • Challenges in assessment of DILI in obese diabetic individuals • Emerging trends in clinical assessment of DILI	
15:30-16:00	Coffee Break , Exhibition & Poster Viewing	
16:00-18:00	Session 7: NASH in pediatric practice • Is NAFLD in children a real health issue? • Is NAFLD in children the same disease as in adults? • Perspectives on NAFLD from a pediatric endocrinology clinic • The Trans-Atlantic Pediatric NASH-TARGET study Panel Discussion (Best practices)	
18:00-	Reception, Poster Awards	

SATURDAY, JUNE 3, 2017

Time	Hall A	Hall B
08:00-09:30	Session 8: Liver-related outcomes in NAFLD The bidirectional evolution of NAFLD The GREAT DEBATE- Is it time to drop liver histology as the anchor for assessment of NAFLD evolution?	
09:30-10:00	Coffee Break , Exhibition & Poster Viewing	
10:00-12:00	Session 9: The diagnostic tools for the clinician to assess NAFLD - Clinical-laboratory assessment of NAFLD - Imaging and Elastography-based approaches - Best practices in disease assessment in daily care Panel	
12:00-13:30	Lunch, Exhibition & Poster Viewing	
12:00-13:30	Meet the Professor A: Managing cardiovascular risk in your patient with NAFLD B: Management issues in Bariatrics	Meet the Professor C: Evaluation of the patient with NAFLD D: Best practices in pediatric NAFLD
13:30-15:30	Session 10: What to do when you find the disease – Behavior modification - Managing the low risk patient...providing practical advice regarding diet and exercise - Food addiction, impulsivity and eating disorders in patients with NAFLD - Anxiety, depression, stress and pain in obesity and NAFLD - is it relevant? - Alcohol consumption in the obese diabetic subject- how much or how little Panel Discussion	
15:30-16:00	Coffee Break , Exhibition & Poster Viewing	
16:00-18:00	Session 11: Therapeutic Landscape for NASH - Current compounds in pivotal trials - Targets under evaluation in early phase trials - Drugs you can use in your office today - Bariatric surgery-what is its role Panel Discussion	
18:00-18:15	Closing Remarks	